From the perspective of China's healthcare system, SUG-CAP as a first-line treatment for advanced G/GEJ adenocarcinoma with PD-L1 CPS ≥5 may not be cost-effective compared with chemotherapy alone. Here, CD274 is linked to gastroesophageal junction adenocarcinoma.